Literature DB >> 15239347

The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas.

Banu Lebe1, Ozgül Sağol, Cağnur Ulukuş, Ahmet Coker, Sedat Karademir, Hüseyin Astarcioglu, Ali Küpelioğlu, Ibrahim Astarcioğlu, Funda Obuz.   

Abstract

The aim of this study was to evaluate the role of cyclin D1 and Ki67 proteins involved in cell-cycle control as a prognostic factor in pancreatic carcinomas. We examined formalin-fixed, paraffin-embedded material from 59 pancreatic adenocarcinomas, for which appropriate clinical and prognostic data were available. The standard streptavidin biotin immunoperoxidase method was used for immunostaining with cyclin D1 and Ki67. The extent of positive nuclear and cytoplasmic cyclin D1 staining was graded semiquantitatively. Ki67 reactivity was quantified and expressed as the percentage of stained nuclei. Staining with cyclin D1 and Ki67 was compared with histopathological prognostic features, and their relation with survival was also tested statistically. Patients whose tumors were cyclin D1-positive showed perineural invasion significantly more frequently than did patients with cyclin D1-negative tumors at the immunohistochemical level. In addition, tumors with lymphatic vessel invasion and without showed a significant difference in terms of cytoplasmic cyclin D1 staining. Ki67 indices were statistically different in stage groups. There was a significant and direct correlation between Ki67 index and nuclear cyclin D1 staining scores. No relation with survival was found. Our results suggest that cell-cycle proteins do not directly affect the prognosis of patients with pancreatic adenocarcinoma. Conversely, cyclin D1-positive tumors tend to have perineural invasion more frequently. In addition, lymph vessel invasion is another factor related to cyclin D1 reactivity of the cells. Ki67 indices differ statistically in stage groups.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15239347     DOI: 10.1016/j.prp.2004.02.010

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

1.  The molecular targets for the diagnosis and treatment of pancreatic cancer.

Authors:  Alexios S Strimpakos; Kostas N Syrigos; Muhammad Wasif Saif
Journal:  Gut Liver       Date:  2010-12-17       Impact factor: 4.519

2.  Phenethyl isothiocyanate inhibits proliferation and induces apoptosis in pancreatic cancer cells in vitro and in a MIAPaca2 xenograft animal model.

Authors:  Silvia D Stan; Shivendra V Singh; David C Whitcomb; Randall E Brand
Journal:  Nutr Cancer       Date:  2013-11-06       Impact factor: 2.900

3.  Cyclin D1 immunoreactivity in meningiomas.

Authors:  Sanja Milenković; Tatjana Marinkovic; Milan B Jovanovic; Slavisa Djuricic; Ivana I Berisavac; Iva Berisavac
Journal:  Cell Mol Neurobiol       Date:  2008-04-01       Impact factor: 5.046

4.  Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.

Authors:  Maria Feldt; Olöf Bjarnadottir; Siker Kimbung; Karin Jirström; Pär-Ola Bendahl; Srinivas Veerla; Dorthe Grabau; Ingrid Hedenfalk; Signe Borgquist
Journal:  J Transl Med       Date:  2015-04-29       Impact factor: 5.531

5.  Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer.

Authors:  R Qin; T C Smyrk; N R Reed; R L Schmidt; T Schnelldorfer; S T Chari; G M Petersen; A H Tang
Journal:  Br J Cancer       Date:  2015-01-13       Impact factor: 7.640

6.  Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth.

Authors:  S J Deharvengt; J R Gunn; S B Pickett; M Korc
Journal:  Cancer Gene Ther       Date:  2009-10-23       Impact factor: 5.987

Review 7.  Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma.

Authors:  Jingbo Li; Rui Kang; Daolin Tang
Journal:  Cancer Commun (Lond)       Date:  2021-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.